Company / R&D per Share
Johnson & Johnson R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.04
FY2025
5-year range
$0.00 / $0.69
FY2021-FY2025
Trend
-93.8%
vs FY2024
Sector context
#202 of 208
Health Care
What the data says
Among 208 Health Care companies, Johnson & Johnson is in the bottom 3% for r&d per share. Declined from $0.18 to $0.04 over the past 2 years.
Based on SEC 10-K filings.
0.04 in FY2025 with a 5-year CAGR of -60.6%.
Declined from $0.18 to $0.04 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -60.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 208This company $0.04 Sector average $28.77
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 93.8% year-over-year.
- Ranks #202 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2022.
Company context
Key Data Points
- Strong profit margin: 27.3%
- Strong return on equity: 31.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.04 | -93.8% |
| FY2024 | $0.69 | +282.6% |
| FY2023 | $0.18 | - |
| FY2022 | $0.00 | - |
| FY2021 | $0.00 | -100.0% |
| FY2020 | $4.46 | +7.7% |
| FY2019 | $4.14 | +7.1% |
| FY2018 | $3.86 | +2.6% |
| FY2017 | $3.77 | +18.0% |
| FY2016 | $3.19 | +1.5% |
As of FY2025 · SEC 10-K · Updated Mar 11, 2026